A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-025-60394-0
Affiliations:
18
Authors:
24
Go to article
Institutions Authors Share
Fred Hutchinson Cancer Center, United States of America (USA)
16.416667
16.416667
 0.68
UW Medicine, United States of America (USA)
2.083333
 0.09
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
1.333333
 0.06
Boston Medical Center (BMC), United States of America (USA)
1.000000
 0.04
Providence Swedish, United States of America (USA)
0.666667
 0.03
Cape Town HVTN Immunology Laboratory (CHIL) / Hutchinson Centre Research Institute of South Africa, South Africa
0.500000
 0.02
BMS Switzerland, Switzerland
0.333333
 0.01
Charité - University Medicine Berlin, Germany
0.333333
 0.01
Berlin Institute of Health (BIH), Germany
0.333333
 0.01
University Hospital of Lausanne (CHUV), UNIL, Switzerland
0.250000
 0.01
University of Lausanne (UNIL), Switzerland
0.250000
 0.01
AGORA Cancer Research Center, Switzerland
0.250000
 0.01
Swiss Institute of Bioinformatics (SIB), Switzerland
0.250000
 0.01
Interested in Oncology and Carcinogenesis?